Disease · MONDO_0007743

attention deficit-hyperactivity disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. attention deficit-hyperactivity disorder. Diseases, record MONDO_0007743. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007743

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: attention deficit-hyperactivity disorder; Open Targets
Open Targets ID: MONDO_0007743; Open Targets
Other names: ADDH, ADHD, ATTENTION DEFICIT DIS, ATTENTION DEFICIT DIS WITH HYPERACTIVITY, ATTENTION DEFICIT HYPERACTIVITY DIS, Attention Deficit Disorder, Attention Deficit Disorder with Hyperactivity, Attention Deficit Disorders, Attention Deficit Disorders with Hyperactivity, Attention Deficit Hyperactivity Disorders, Brain Dysfunction, Minimal, Deficit Disorder, Attention, Deficit Disorders, Attention, Disorder, Attention Deficit, Disorders, Attention Deficit, Dysfunction, Minimal Brain, Hyperkinetic Syndrome, Minimal Brain Dysfunction, Syndromes, Hyperkinetic; Open Targets
NCI Thesaurus: C97160; NCI Thesaurus
Highest stage of its drugs: Approval, for 52 of its 135 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs135

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METHYLPHENIDATE	CHEMBL796	Small molecule	Approval	ATC, DailyMed and TTD	194	181	177	Drugs and targets
ATOMOXETINE	CHEMBL641	Small molecule	Approval	ATC and TTD	88	86	86	Drugs and targets
METHYLPHENIDATE HYDROCHLORIDE	CHEMBL1722	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	62	44	44	Drugs and targets
AMPHETAMINE	CHEMBL405	Small molecule	Approval	ATC, DailyMed and TTD	51	44	31	Drugs and targets
LISDEXAMFETAMINE DIMESYLATE	CHEMBL1201178	Small molecule	Approval	DailyMed and PMDA	38	34	34	Drugs and targets
GUANFACINE	CHEMBL862	Small molecule	Approval	EMA Human Drugs and TTD	20	17	17	Drugs and targets
LISDEXAMFETAMINE	CHEMBL1201222	Small molecule	Approval	ATC and TTD	18	16	16	Drugs and targets
ATOMOXETINE HYDROCHLORIDE	CHEMBL1702	Small molecule	Approval	DailyMed, FDA and PMDA	30	15	15	Drugs and targets
GUANFACINE HYDROCHLORIDE	CHEMBL1200494	Small molecule	Approval	DailyMed, PMDA and TTD	17	11	11	Drugs and targets
DEXTROAMPHETAMINE SULFATE	CHEMBL3544971	Small molecule	Approval	DailyMed	10	9	9	Drugs and targets

1 to 10 of 135

See all 135 drugs

Targets87

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A2	Monoamine transporter	31	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
SLC6A3	Monoamine transporter	24	Dopamine transporter inhibitor; Dopamine transporter releasing agent; Monoamine transporter inhibitor	Approval	https://conductscience.org/library/genes/6531	Drugs and targets
SLC6A4	Monoamine transporter	10	Monoamine transporter inhibitor; Serotonin transporter inhibitor	Approval	https://conductscience.org/library/genes/6532	Drugs and targets
DRD2	D(2) dopamine receptor	6	D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	6	Serotonin 2a (5-HT2a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
ADRA2A	Adrenergic receptor	5	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	5	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	5	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	5	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist; Nicotinic acetylcholine receptor alpha4/beta2/alpha5 partial agonist	Phase 2	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	5	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist; Neuronal acetylcholine receptor; alpha6/beta2 partial agonist; Nicotinic acetylcholine receptor alpha4/beta2/alpha5 partial agonist	Phase 2	https://conductscience.org/library/genes/1141	Drugs and targets

1 to 10 of 87

See all 87 targets

Trials510

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 19 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00700427	A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)	Phase 3	2,017	2013-05-29	Attention Deficit Hyperactivity Disorder	ATOMOXETINE	Its record names the disease	ClinicalTrials.gov
NCT00190684	Long-Term, Open Label Atomoxetine Study	Phase 3	1,553	2011-01-17	Attention Deficit Hyperactivity Disorder	ATOMOXETINE	Its record names the disease	ClinicalTrials.gov
NCT01074294	Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder	Phase 2	740	2023-02-02	Attention Deficit Hyperactivity Disorder	BREXPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01259492	Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)	Phase 3	725	2014-04-29	Attention Deficit/Hyperactivity Disorder	METHYLPHENIDATE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT03605849	A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder	Phase 3	662	2024-10-01	Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder	CENTANAFADINE	Its record names the disease	ClinicalTrials.gov
NCT03605680	A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder	Phase 3	604	2021-05-05	Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder	CENTANAFADINE	Its record names the disease	ClinicalTrials.gov
NCT03605836	A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder	Phase 3	590	2021-10-18	Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder	CENTANAFADINE	Its record names the disease	ClinicalTrials.gov
NCT01552902	Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder	Phase 4	549	2015-03-18	Attention-deficit/Hyperactivity Disorder	LISDEXAMFETAMINE DIMESYLATE, METHYLPHENIDATE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01081145	Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)	Phase 3	528	2014-06-09	Attention-deficit/Hyperactivity Disorder	GUANFACINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00190775	A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)	Phase 4	502	2010-10-21	Attention Deficit Hyperactivity Disorder	ATOMOXETINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 510

See all 510 trials

Comparisons in its trials163

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
All Ritalin LA vs Placebo: serious adverse events	9 of 695	4 of 275	970	NCT01259492	Trial comparisons
Atomoxetine vs Placebo: serious adverse events	4 of 266	3 of 234	500	NCT00190775	Trial comparisons
Atomoxetine vs Placebo: serious adverse events	1 of 220	1 of 225	445	NCT00510276	Trial comparisons
Atomoxetine vs OEST: serious adverse events	2 of 199	2 of 199	398	NCT00447278	Trial comparisons
Atomoxetine vs Placebo: serious adverse events	1 of 193	2 of 195	388	NCT00962104	Trial comparisons
SPN-812 vs Placebo: deaths from any cause	0 of 189	0 of 183	372	NCT04016779	Trial comparisons
SPN-812 vs Placebo: serious adverse events	0 of 189	2 of 183	372	NCT04016779	Trial comparisons
OROS MPH vs PLACEBO: serious adverse events	0 of 174	1 of 175	349	NCT00937040	Trial comparisons
Edivoxetine (Open-Label) vs Edivoxetine (Follow Up): serious adverse events	7 of 264	1 of 80	344	NCT00965419	Trial comparisons
SPD503 vs PLACEBO: serious adverse events	4 of 157	2 of 155	312	NCT01081132	Trial comparisons

1 to 10 of 163

See all 163 comparisons in its trials

Papers from its trials443

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34167656	RESULT	1	PubMed
33669651	RESULT	1	PubMed
31313248	RESULT	1	PubMed
30978259	RESULT	1	PubMed
30911234	RESULT	1	PubMed
30877269	RESULT	1	PubMed
30762452	RESULT	1	PubMed
30299126	RESULT	1	PubMed
30191748	RESULT	1	PubMed
30097390	RESULT	1	PubMed

1 to 10 of 443

See all 443 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007743

GET https://conductscience.org/api/diseases/v1/MONDO_0007743/drugs?page=2

API reference For AI assistants